{
    "symbol": "SGHT",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-13 22:23:06",
    "content": " We continue to advance our growth initiatives which include: one, expanding the large and growing moderate to advanced combination cataract segment and the considerably larger standalone MIGS segment with OMNI\u00e2\u0080\u0099s differentiated efficacy profile; two, driving adoption and utilization of SION among specific subsets of surgeons, who choose a more basic procedure; and three, increasing our total share of MIGS with our OMNI and SION technologies. Our Dry Eye revenues for the fourth quarter were $1.8 million, up 135% year-over-year and up to 12% sequentially. Your line is open. Please stand by for our next question. Your line is open. Please stand by for our next question. Your line is open. Please stand by for our next question. Your line is open. Please stand by for our next question. Your line is open. Please stand by for our next question. Please stand by for our next question. Your line is open. I think we're seeing very little of it based on the account, as Paul said, his remarks based on the accounts that ordered OMNI in the fourth quarter of 2021 and OMNI and SION in the fourth quarter of 2022, utilization of OMNI actually increased by 12%."
}